Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Featured Articles

Original Article
Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Read More
Original Article
Assessment of the Elimination of Test Doses for Paclitaxel and Carboplatin in Patients with Cancer
Read More
Original Article
Outcomes and Adverse Events Linked to Off-Label Treatment of Solid Tumors with PARP Inhibitors
Read More
Review Article
Pancreatic Cancer: Review of the Current and Investigational Drug Landscape
Read More
Case Reports
Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report
Read More
Case Reports
The Presence of De Novo EGFR T790M Mutation in a Tyrosine Kinase Inhibitor–Naïve Patient with Lung Adenocarcinoma: Case Report and Review of the Literature
Read More

Thank You JHOP Peer Reviewers

The Editors and Publisher of the Journal of Hematology Oncology Pharmacy (JHOP) wish to express their gratitude to the many hematology oncology pharmacists and other healthcare professionals who have contributed their expertise in the peer-review process...
CONTINUE READING

FDA Oncology Update

Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer
Read More
Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation
Read More
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma
Read More
Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma
Read More
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer
Read More
Rylaze Received FDA Approval of a New Dosing Regimen
Read More
Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
Read More
Libtayo plus Platinum-Based Chemotherapy Now FDA Approved for NSCLC without Genomic Aberrations
Read More

Most Popular Articles

August 2022 Clinical Trials to Clinical Practice - Clinical Trials, Melanoma
Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy
JHOP - October 2022 Vol 12, No 5 - Original Article
Time to First Palbociclib Prescription Dispense at Mayo Clinic: Comparing a Health-System Specialty Pharmacy with External Specialty Pharmacies
JHOP - October 2022 Vol 12, No 5 - Original Article
Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting
JHOP - October 2022 Vol 12, No 5 - Original Article
Evaluating Institutional Safety Standards Related to Continuing Oral Antineoplastic Medication Use During Hospitalization
JHOP - August 2022 Vol 12, No 4 - Original Article, Prostate Cancer, Genitourinary Cancers, Targeted Therapies
Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer
JHOP - October 2022 Vol 12, No 5 - Practical Issues in Pharmacy Management
Implementation and Evaluation of a Formal Investigational Drug Service at a Community Cancer Center


Copyright © The Lynx Group, LLC. All rights reserved.